Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes

被引:22
作者
Eastwood, Brian [1 ,2 ]
Strang, John [1 ]
Marsden, John [1 ,2 ]
机构
[1] Kings Coll London, Addict Dept, Inst Psychiat Psychol & Neurosci, Box 48,DeCrespigny Pk,Denmark Hill, London SE5 8AF, England
[2] Publ Hlth England, Hlth Improvement Directorate, Alcohol Drugs Tobacco & Justice Div, 7 Floor,Wellington House,133-155 Waterloo Rd, London SE1 8UG, England
关键词
Treatment effectiveness; Opioid use disorder; National; Developmental trajectory; USE DISORDER; FOLLOW-UP; DRUG; 5-YEAR; REDUCTIONS; ADDICTION; RECOVERY; RISK;
D O I
10.1016/j.drugalcdep.2018.03.052
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: This is the first national study in England of continuous long-term opioid substitution treatment (OST). Methods: All adults were admitted to community OST for opioid use disorder (OUD) in 2008/09 with continuous enrolment to 2013/14 (n = 7719). Heroin use trajectories were identified by multilevel Latent Class Growth Analysis. In Year 6 and 7 of follow-up, the outcome measure (analysed by multilevel, multivariable logistic regression) was 'successful completion and no re-presentation' (SCNR) to community treatment within six months. Results: Five heroin use trajectory classes were identified: 'gradual decreasing' (20.9%), 'decreasing then increasing' (21.7%), 'continued low-level' (17.0%), 'rapid decreasing' (25.6%), and 'continued high-level' (14.8%). At the end of Year 7, 4616 people (60.3%) remained in OST. Of those discharged, 28.8% achieved the SCNR follow-up outcome. SCNR was more likely in the 'gradual decreasing' (adjusted odds ratio [AOR] 2.40; 95% confidence interval [CI] 1.77-3.26), 'continued low-level' (AOR 2.46; CI 1.78-3.40), and 'rapid decreasing' (AOR 3.40; CI 2.43-4.37) classes relative to the 'continued high-level' class. SCNR was more likely among patients employed at admission (AOR 1.45; 95% CI 1.15-1.83) and those receiving adjunctive psychosocial interventions (AOR 1.44; 95% CI 1.03 to 2.02). Conclusions: Among English patients in OST for 5 years, heroin use trajectories were clearly delineated with a gradient of response on the study outcome. Successful completion and no re-presentation was achieved by 28.8% of discharged patients. The rapid decreasing trajectory had the greatest likelihood of positive outcome. Adjunctive psychosocial intervention during OST was associated with positive outcome.
引用
收藏
页码:200 / 208
页数:9
相关论文
共 50 条
  • [41] Treatment for opioid use and outcomes in older adults: a systematic literature review
    Carew, Anne Marie
    Comiskey, Catherine
    DRUG AND ALCOHOL DEPENDENCE, 2018, 182 : 48 - 57
  • [42] Modelling Long-Term Joint Trajectories of Heroin Use and Treatment Utilisation: Findings from the Australian Treatment Outcome Study
    Marel, Christina
    Mills, Katherine L.
    Slade, Tim
    Darke, Shane
    Ross, Joanne
    Teesson, Maree
    ECLINICALMEDICINE, 2019, 14 : 71 - 79
  • [43] Treatment approaches and outcome trajectories for youth with high-risk opioid use: A narrative review
    Westenberg, Jean Nicolas
    Tai, Andy M. Y.
    Elsner, Julie
    Kamel, Mostafa M.
    Wong, James S. H.
    Azar, Pouya
    Vo, Dzung X.
    Moore, Eva
    Mathew, Nickie
    Seethapathy, Vijay
    Choi, Fiona
    Vogel, Marc
    Krausz, Reinhard M.
    EARLY INTERVENTION IN PSYCHIATRY, 2022, 16 (03) : 207 - 220
  • [44] Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use
    Ellis, Jennifer D.
    Rabinowitz, Jill A.
    Wells, Jonathan
    Liu, Fangyu
    Finan, Patrick H.
    Stein, Michael D.
    Antoine, Denis G., II
    Hobelmann, Gregory J.
    Huhn, Andrew S.
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 299 : 223 - 232
  • [45] Social functioning outcomes in men and women receiving medication-assisted treatment for opioid use disorder
    van Reekum, Emma A.
    Rosic, Tea
    Hudson, Jacqueline
    Sanger, Nitika
    Marsh, David C.
    Worster, Andrew
    Thabane, Lehana
    Samaan, Zainab
    BIOLOGY OF SEX DIFFERENCES, 2020, 11 (01)
  • [46] Opioid agonist therapy during residential treatment of opioid use disorder Cohort study on access and outcomes
    Spithoff, Sheryl
    Meaney, Christopher
    Urbanoski, Karen
    Harrington, Katy
    Que, Bill
    Kahan, Meldon
    Leece, Pamela
    Shehadeh, Vivian
    Sullivan, Frank
    CANADIAN FAMILY PHYSICIAN, 2019, 65 (10) : E443 - E452
  • [47] Trajectories of Injection Drug Use Over 20 Years (1988-2008) in Baltimore, Maryland
    Genberg, Becky L.
    Gange, Stephen J.
    Go, Vivian F.
    Celentano, David D.
    Kirk, Gregory D.
    Mehta, Shruti H.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 (07) : 829 - 836
  • [48] Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care
    Williams, Arthur Robin
    Mauro, Christine M.
    Chiodo, Lisa
    Huber, Ben
    Cruz, Angelo
    Crystal, Stephen
    Samples, Hillary
    Nowels, Molly
    Wilson, Amanda
    Friedmann, Peter D.
    Remien, Robert H.
    Olfson, Mark
    DRUG AND ALCOHOL DEPENDENCE, 2024, 263
  • [49] Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
    Kennedy-Hendricks, Alene
    Schilling, Cameron J.
    Busch, Alisa B.
    Stuart, Elizabeth A.
    Huskamp, Haiden A.
    Meiselbach, Mark K.
    Barry, Colleen L.
    Eisenberg, Matthew D.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (04) : 769 - 776
  • [50] Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
    Alene Kennedy-Hendricks
    Cameron J. Schilling
    Alisa B. Busch
    Elizabeth A. Stuart
    Haiden A. Huskamp
    Mark K. Meiselbach
    Colleen L. Barry
    Matthew D. Eisenberg
    Journal of General Internal Medicine, 2022, 37 : 769 - 776